178 related articles for article (PubMed ID: 23534729)
1. XPD Lys751Gln and Asp312Asn polymorphisms and gastric cancer susceptibility: a meta-analysis of case-control studies.
Yin QH; Liu C; Hu JB; Meng RR; Li L; Wang YJ
Asian Pac J Cancer Prev; 2013; 14(1):231-6. PubMed ID: 23534729
[TBL] [Abstract][Full Text] [Related]
2. Xeroderma pigmentosum group D polymorphisms and esophageal cancer susceptibility: a meta-analysis based on case-control studies.
Yang R; Zhang C; Malik A; Shen ZD; Hu J; Wu YH
World J Gastroenterol; 2014 Nov; 20(44):16765-73. PubMed ID: 25469049
[TBL] [Abstract][Full Text] [Related]
3. Lack of association between XPD Lys751Gln and Asp312Asn polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies.
Zhang Y; Ding D; Wang X; Zhu Z; Huang M; He X
Int J Colorectal Dis; 2011 Oct; 26(10):1257-64. PubMed ID: 21541661
[TBL] [Abstract][Full Text] [Related]
4. XPD Lys751Gln and Asp312Asn polymorphisms and susceptibility to skin cancer: a meta-analysis of 17 case-control studies.
Zhu HL; Bao JM; Lin PX; Li WX; Zou ZN; Huang YE; Chen Q; Shen H
Asian Pac J Cancer Prev; 2014; 15(16):6619-25. PubMed ID: 25169498
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of xeroderma pigmentosum group D gene Asp312Asn and Lys751Gln and susceptibility to prostate cancer: a systematic review and meta-analysis.
Ma Q; Qi C; Tie C; Guo Z
Gene; 2013 Nov; 530(2):309-14. PubMed ID: 23973729
[TBL] [Abstract][Full Text] [Related]
6. Association between XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma risk: a systematic review and meta-analysis.
Peng Q; Li S; Lao X; Chen Z; Li R; Qin X
Medicine (Baltimore); 2014 Dec; 93(29):e330. PubMed ID: 25546681
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in XPD (Asp312Asn and Lys751Gln) genes, sunburn and arsenic-related skin lesions.
McCarty KM; Smith TJ; Zhou W; Gonzalez E; Quamruzzaman Q; Rahman M; Mahiuddin G; Ryan L; Su L; Christiani DC
Carcinogenesis; 2007 Aug; 28(8):1697-702. PubMed ID: 17470448
[TBL] [Abstract][Full Text] [Related]
8. XPD Lys
Yang QI; Wei YF; Zhang Y; Huang GM
Exp Ther Med; 2015 Jun; 9(6):2406-2414. PubMed ID: 26136996
[TBL] [Abstract][Full Text] [Related]
9. Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis.
Li SX; Dai QS; Chen SX; Zhang SD; Liao XY; Deng X; Chi HB; Li FJ; Zhu JH; Jiang YY
Tumour Biol; 2014 Apr; 35(4):3905-15. PubMed ID: 24347488
[TBL] [Abstract][Full Text] [Related]
10. Association of the Asp312Asn and Lys751Gln polymorphisms in the XPD gene with the risk of non-Hodgkin's lymphoma: evidence from a meta-analysis.
Chen S; Zhu JH; Wang F; Huang SY; Xue WQ; Cui Z; He J; Jia WH
Chin J Cancer; 2015 Mar; 34(3):108-14. PubMed ID: 25962431
[TBL] [Abstract][Full Text] [Related]
11. The effect of XPD/ERCC2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis.
Xue H; Lu Y; Lin B; Chen J; Tang F; Huang G
PLoS One; 2012; 7(9):e43431. PubMed ID: 23028453
[TBL] [Abstract][Full Text] [Related]
12. XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: a meta-analysis.
Yan Y; Liang H; Light M; Li T; Deng Y; Li M; Li S; Qin X
Tumour Biol; 2014 Mar; 35(3):1907-15. PubMed ID: 24101192
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive assessment of associations between ERCC2 Lys751Gln/Asp312Asn polymorphisms and risk of non- Hodgkin lymphoma.
Zhou JY; He LW; Liu J; Yu HL; Wei M; Ma WL; Shi R
Asian Pac J Cancer Prev; 2014; 15(21):9347-53. PubMed ID: 25422223
[TBL] [Abstract][Full Text] [Related]
14. XPD Lys751Gln polymorphisms and the risk of esophageal cancer: an updated meta-analysis.
Guo XF; Wang J; Lei XF; Zeng YP; Dong WG
Intern Med; 2015; 54(3):251-9. PubMed ID: 25748732
[TBL] [Abstract][Full Text] [Related]
15. XPD polymorphisms, cigarette smoking, and bladder cancer risk: a meta-analysis.
Wang M; Gu D; Zhang Z; Zhou J; Zhang Z
J Toxicol Environ Health A; 2009; 72(11-12):698-705. PubMed ID: 19492231
[TBL] [Abstract][Full Text] [Related]
16. XPD Lys751Gln polymorphism and esophageal cancer susceptibility: a meta-analysis of case-control studies.
Ding DP; Ma WL; He XF; Zhang Y
Mol Biol Rep; 2012 Mar; 39(3):2533-40. PubMed ID: 21667112
[TBL] [Abstract][Full Text] [Related]
17. Association between XPD Asp312Asn polymorphism and esophageal cancer susceptibility: a meta-analysis.
Duan XL; Gong H; Zeng XT; Ni XB; Yan Y; Chen W; Liu GL
Asian Pac J Cancer Prev; 2012; 13(7):3299-303. PubMed ID: 22994751
[TBL] [Abstract][Full Text] [Related]
18. ERCC2/XPD Lys751Gln and Asp312Asn gene polymorphism and lung cancer risk: a meta-analysis involving 22 case-control studies.
Zhan P; Wang Q; Wei SZ; Wang J; Qian Q; Yu LK; Song Y
J Thorac Oncol; 2010 Sep; 5(9):1337-45. PubMed ID: 20651612
[TBL] [Abstract][Full Text] [Related]
19. The association between XPD Asp312Asn polymorphism and lung cancer risk: a meta-analysis including 16,949 subjects.
Zhang J; Qiu LX; Leaw SJ; Hu XC; Chang JH
Med Oncol; 2011 Sep; 28(3):655-60. PubMed ID: 20354818
[TBL] [Abstract][Full Text] [Related]
20. XPD Asp312Asn polymorphism is a risk factor for prostate cancer.
Liao SG; Liu L; Wang Y; Zhang YY; Wang YJ
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1689-95. PubMed ID: 22644997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
